Bronkolin

Bronkolin may be available in the countries listed below.

Ingredient matches for Bronkolin

Theophylline

Theophylline is reported as an ingredient of Bronkolin in the following countries:

• Turkey

International Drug Name Search

Starval

Starval may be available in the countries listed below.

Ingredient matches for Starval

Valsartan

Valsartan is reported as an ingredient of Starval in the following countries:

• India


• Peru

International Drug Name Search

Pancuronium Inresa

Pancuronium Inresa may be available in the countries listed below.

Ingredient matches for Pancuronium Inresa

Pancuronium

Pancuronium Bromide is reported as an ingredient of Pancuronium Inresa in the following countries:

• Germany

International Drug Name Search

Initiss

Initiss may be available in the countries listed below.

Ingredient matches for Initiss

Cilazapril

Cilazapril is reported as an ingredient of Initiss in the following countries:

• Italy

International Drug Name Search

Sodium Benzoate

Sodium Benzoate may be available in the countries listed below.

Ingredient matches for Sodium Benzoate

Benzoic Acid

Sodium Benzoate (JAN, USAN) is known as Benzoic Acid in the US.

International Drug Name Search

Glossary

JAN	Japanese Accepted Name
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Triaderm

Triaderm may be available in the countries listed below.

Ingredient matches for Triaderm

Triamcinolone

Triamcinolone 16α,17α-acetonide (a derivative of Triamcinolone) is reported as an ingredient of Triaderm in the following countries:

• Canada

International Drug Name Search

Januvia

Januvia is a brand name of sitagliptin, approved by the FDA in the following formulation(s):

JANUVIA (sitagliptin phosphate - tablet; oral)

• 
  Manufacturer: MERCK CO INC
  
  Approval date: October 16, 2006
  
  Strength(s): EQ 100MG BASE ^[RLD], EQ 25MG BASE, EQ 50MG BASE
  

Has a generic version of Januvia been approved?

No. There is currently no therapeutically equivalent version of Januvia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Januvia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
  Patent 6,303,661
  Issued: October 16, 2001
  Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
  Assignee(s): Probiodrug
  Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
  
  Patent expiration dates:
  
  
  • April 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
  
  



• 
  Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  Patent 6,699,871
  Issued: March 2, 2004
  Inventor(s): Scott D.; Edmondson & Michael H.; Fisher & Dooseop; Kim & Malcolm; Maccoss & Emma R.; Parmee & Ann E.; Weber & Jinyou; Xu
  Assignee(s): Merck & Co., Inc.
  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
  
  Patent expiration dates:
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 6,890,898
  Issued: May 10, 2005
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  1149336 Ontario Inc.
  New England Medical Center Hospitals, Inc.
  The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,078,381
  Issued: July 18, 2006
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
  
  



• 
  Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  Patent 7,125,873
  Issued: October 24, 2006
  Inventor(s): Edmondson; Scott D & Fisher; Michael H. & Kim; Dooseop & Maccoss; Malcolm & Parmee; Emma R. & Weber; Ann E & Xu; Jinyou
  Assignee(s): Merck & Co., Inc.
  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
  
  Patent expiration dates:
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
  
  



• 
  Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
  Patent 7,326,708
  Issued: February 5, 2008
  Inventor(s): Cypes; Stephen Howard & Chen; Alex Minhua & Ferlita; Russell R. & Hansen; Karl & Lee; Ivan & Vydra; Vicky K. & Wenslow, Jr.; Robert M.
  Assignee(s): Merck & Co., Inc.
  The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.
  
  Patent expiration dates:
  
  
  • April 11, 2026
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 12, 2010 - DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
  
  
  • October 12, 2010 - RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
  
  
  • October 16, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Januvia Consumer Information (Drugs.com)
• Januvia Consumer Information (Wolters Kluwer)
• Januvia Consumer Information (Cerner Multum)
• Januvia Advanced Consumer Information (Micromedex)
• Januvia AHFS DI Monographs (ASHP)
• Sitagliptin Consumer Information (Wolters Kluwer)
• Sitagliptin Consumer Information (Cerner Multum)
• Sitagliptin Advanced Consumer Information (Micromedex)
• Sitagliptin Phosphate AHFS DI Monographs (ASHP)

Doramectin

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0117704-25-3

Chemical Formula

C50-H74-O14

Molecular Weight

899

Therapeutic Categories

Anthelmintic

Ectoparasiticide

Chemical Name

Avermectin A₁a, 25-cyclohexyl-5-O-demethyl-25-de(1-methylpropyl)-

Foreign Names

• Doramectinum (Latin)
• Doramectin (German)
• Doramectine (French)
• Doramectina (Spanish)

Generic Names

• Doramectin (OS: USAN, BAN)
• UK 67994 (IS: Pfizer)

Brand Names

• Dectomax (veterinary use)
  Botéba, Netherlands; Novivet, Netherlands; Orion, Sweden; Pfizer, Austria; Pfizer, Poland; Pfizer Animal, Portugal; Pfizer Animal Health, Australia; Pfizer Animal Health, Belgium; Pfizer Animal Health, Switzerland; Pfizer Animal Health, Finland; Pfizer Animal Health, United Kingdom; Pfizer Animal Health, Ireland; Pfizer Animal Health, Italy; Pfizer Animal Health, Luxembourg; Pfizer Animal Health, Netherlands; Pfizer Animal Health, Norway; Pfizer Animal Health, New Zealand; Pfizer Animal Health, United States; Pfizer Animal Health, South Africa; Pfizer GmbH Tiergesundheit, Germany; Pfizer Santé Animale, France



• Dectomax-S (veterinary use)
  Pfizer GmbH Tiergesundheit, Germany



• Prontax (veterinary use)
  Pfizer Animal Health, Netherlands

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Mevalotin

Mevalotin may be available in the countries listed below.

Ingredient matches for Mevalotin

Pravastatin

Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Mevalotin in the following countries:

• Brazil


• China


• Germany


• Japan


• Switzerland


• Taiwan


• Venezuela

International Drug Name Search

Your Pharmacy Aciclovir

Your Pharmacy Aciclovir may be available in the countries listed below.

Ingredient matches for Your Pharmacy Aciclovir

Acyclovir

Aciclovir is reported as an ingredient of Your Pharmacy Aciclovir in the following countries:

• Australia

International Drug Name Search

Bexatus

Bexatus may be available in the countries listed below.

Ingredient matches for Bexatus

Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Bexatus in the following countries:

• Spain

International Drug Name Search

Purinol

Purinol may be available in the countries listed below.

Ingredient matches for Purinol

Allopurinol

Allopurinol is reported as an ingredient of Purinol in the following countries:

• Austria


• Czech Republic


• Ireland


• Oman


• Russian Federation


• Tunisia

Methenamine

Methenamine anhydromethylencitrate (a derivative of Methenamine) is reported as an ingredient of Purinol in the following countries:

• Turkey

International Drug Name Search

dorzolamide ophthalmic

Generic Name: dorzolamide ophthalmic (dor ZOL a mide)

Brand Names: Trusopt

What is dorzolamide ophthalmic?

Dorzolamide reduces the amount of fluid in the eye, which decreases pressure inside the eye.

Dorzolamide ophthalmic (for the eyes) is used to treat open-angle glaucoma and other causes of high pressure inside the eye.

Dorzolamide ophthalmic may also be used for purposes not listed in this medication guide.

What is the most important information I should know about dorzolamide ophthalmic?

Do not allow the dropper to touch any surface, including the eyes or hands. If the dropper becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.

Do not use any other eye medication unless your doctor has prescribed it for you. If you use another eye medication, use it at least 10 minutes before or after using dorzolamide ophthalmic. Do not use the medications at the same time.

Dorzolamide ophthalmic can cause blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.

What should I discuss with my healthcare provider before using dorzolamide ophthalmic?

You should not use this medication if you are allergic to dorzolamide (Trusopt or Cosopt).

To make sure you can safely use dorzolamide ophthalmic, tell your doctor if you have any of these other conditions:

• 
  

  narrow-angle glaucoma;

  
  


• 
  

  kidney disease; or

  
  


• 
  

  liver disease.

  
  

FDA pregnancy category C. It is not known whether dorzolamide ophthalmic will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is not known whether dorzolamide ophthalmic passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use dorzolamide ophthalmic?

Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Do not use this medication while wearing contact lenses. Dorzolamide ophthalmic may contain a preservative that can discolor soft contact lenses. Wait at least 15 minutes after using dorzolamide before putting your contact lenses in.

This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

Wash your hands before using the eye drops.

To apply the eye drops:

• 
  

  Tilt your head back slightly and pull down your lower eyelid to create a small pocket. Hold the dropper above the eye with the tip down. Look up and away from the dropper as you squeeze out a drop, then close your eye.

  
  


• 
  

  Use only the number of drops your doctor has prescribed.

  
  


• 
  

  Gently press your finger to the inside corner of the eye (near your nose) for about 1 minute to keep the liquid from draining into your tear duct.

  
  


• 
  

  If you use more than one drop in the same eye, wait about 5 minutes before putting in the next drop.

  
  


• 
  

  Wait at least 10 minutes before using any other eye drops that your doctor has prescribed.

  
  

Do not allow the dropper tip to touch any surface, including the eyes or hands. If the dropper becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.

Do not use the eye drops if the liquid has changed colors or has particles in it. Call your doctor for a new prescription.

Tell your doctor right away if you have any eye injury or infection, or if you need to have any type of surgery, especially eye surgery. You may need to stop using dorzolamide ophthalmic for a short time.

Store at room temperature away from moisture, heat, and light. Keep the bottle tightly closed when not in use.

What happens if I miss a dose?

Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include dry mouth, increased thirst, drowsiness, restless feeling, confusion, nausea, vomiting, increased urination, muscle pain or weakness, fast heart rate, feeling light-headed, fainting, or seizure (convulsions).

What should I avoid while using dorzolamide ophthalmic?

Dorzolamide ophthalmic may cause blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.

Do not use other eye medications during treatment with dorzolamide ophthalmic unless your doctor tells you to.

Dorzolamide ophthalmic side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Although the risk of serious side effects is low when dorzolamide is used in the eyes, you should be aware of side effects that can occur if the medication is absorbed into your bloodstream.

Stop using dorzolamide ophthalmic and call your doctor at once if you have a serious side effect such as:

• 
  

  swelling or redness of your eyelids;

  
  


• 
  

  eye redness, pain, discomfort, or sensitivity to light;

  
  


• 
  

  drainage, crusting, or oozing of your eyes or eyelids;

  
  


• 
  

  severe skin reaction: fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling; or

  
  


• 
  

  stomach pain, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes).

  
  

Less serious side effects may include:

• 
  

  burning or stinging in your eye;

  
  


• 
  

  bitter or unusual taste in your mouth;

  
  


• 
  

  blurred vision;

  
  


• 
  

  dry or watery eyes;

  
  


• 
  

  headache;

  
  


• 
  

  weakness, tired feeling;

  
  


• 
  

  nausea; or

  
  


• 
  

  dry mouth, sore throat.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Dorzolamide ophthalmic Dosing Information

Usual Adult Dose for Intraocular Hypertension:

Instill 1 drop in the affected eye(s) 3 times daily.

Usual Adult Dose for Glaucoma (Open Angle):

Instill 1 drop in the affected eye(s) 3 times daily.

Usual Pediatric Dose for Intraocular Hypertension:

Instill 1 drop in the affected eye(s) 3 times daily.

Usual Pediatric Dose for Glaucoma (Open Angle):

Instill 1 drop in the affected eye(s) 3 times daily.

What other drugs will affect dorzolamide ophthalmic?

Tell your doctor about all other medicines you use, especially:

• 
  

  acetazolamide (Diamox);

  
  


• 
  

  brinzolamide (Azopt); or

  
  


• 
  

  methazolamide (Neptazane).

  
  

This list is not complete and other drugs may interact with dorzolamide ophthalmic. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More dorzolamide ophthalmic resources

• Dorzolamide ophthalmic Side Effects (in more detail)
• Dorzolamide ophthalmic Dosage
• Dorzolamide ophthalmic Use in Pregnancy & Breastfeeding
• Dorzolamide ophthalmic Drug Interactions
• Dorzolamide ophthalmic Support Group
• 0 Reviews for Dorzolamide - Add your own review/rating

• Trusopt Prescribing Information (FDA)


• Trusopt Monograph (AHFS DI)


• Trusopt Drops MedFacts Consumer Leaflet (Wolters Kluwer)

Compare dorzolamide ophthalmic with other medications

• Glaucoma, Open Angle
• Intraocular Hypertension

Where can I get more information?

• Your pharmacist can provide more information about dorzolamide ophthalmic.

See also: dorzolamide side effects (in more detail)

Co-Tensiol

Co-Tensiol may be available in the countries listed below.

Ingredient matches for Co-Tensiol

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Co-Tensiol in the following countries:

• Slovenia

Olmesartan

Olmesartan Medoxomil is reported as an ingredient of Co-Tensiol in the following countries:

• Slovenia

International Drug Name Search

Espesil

Espesil may be available in the countries listed below.

Ingredient matches for Espesil

Acebutolol

Acebutolol hydrochloride (a derivative of Acebutolol) is reported as an ingredient of Espesil in the following countries:

• Finland

International Drug Name Search

Cetrifarm

Cetrifarm may be available in the countries listed below.

Ingredient matches for Cetrifarm

Cetrimide

Cetrimide is reported as an ingredient of Cetrifarm in the following countries:

• Italy

Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Cetrifarm in the following countries:

• Italy

International Drug Name Search

Orystor

Orystor may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Orystor

Fenbendazole

Fenbendazole is reported as an ingredient of Orystor in the following countries:

• Germany

International Drug Name Search

Desonate

Generic Name: desonide topical (DES oh nide)

Brand Names: Delonide, Desonate, DesOwen, DesOwen 2 oz, DesOwen Lotion 4 oz Kit, LoKara, Tridesilon, Verdeso

What is desonide topical?

Desonide is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.

Desonide topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

Desonide topical may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about desonide topical?

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.

Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with desonide topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period. Contact your doctor if your condition does not improve after 2 weeks of using this medicine, or if you develop signs of a bacterial, fungal, or viral skin infection.

What should I discuss with my healthcare provider before using desonide topical?

Do not use this medication if you are allergic to desonide.

Before using desonide topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.

Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether desonide topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period.

How should I use desonide topical?

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.

Wash your hands before and after using desonide topical, unless you are using the medication to treat the skin on your hands.

Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.

Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with desonide topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Contact your doctor if your condition does not improve after 2 weeks of using this medicine, or if you develop signs of a bacterial, fungal, or viral skin infection. It is important to use desonide topical regularly to get the most benefit.

To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.

Store desonide topical at room temperature away from moisture and heat. Keep from freezing.

What happens if I miss a dose?

Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of desonide is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.

What should I avoid while using desonide topical?

Desonide topical should not be used to treat any skin condition your doctor has not prescribed it for.

Avoid getting this medication in your eyes. If contact does occur, rinse with water. Do not use desonide topical on broken or infected skin. Also avoid using this medication in open wounds.

Desonide topical side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have severe irritation of any treated skin, or if you show signs of absorbing desonide topical through your skin, such as:

• 
  

  blurred vision, or seeing halos around lights;

  
  


• 
  

  mood changes;

  
  


• 
  

  sleep problems (insomnia);

  
  


• 
  

  weight gain, puffiness in your face; or

  
  


• 
  

  muscle weakness, feeling tired.

  
  

Less serious side effects may include:

• 
  

  mild skin itching, redness, burning, or peeling;

  
  


• 
  

  dryness or scaly skin;

  
  


• 
  

  thinning or softening of your skin;

  
  


• 
  

  skin rash or irritation around your mouth;

  
  


• 
  

  swollen hair follicles;

  
  


• 
  

  changes in color of treated skin;

  
  


• 
  

  blisters, pimples, or crusting of treated skin; or

  
  


• 
  

  stretch marks.

  
  

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect desonide topical?

It is not likely that other drugs you take orally or inject will have an effect on topically applied desonide topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More Desonate resources

• Desonate Side Effects (in more detail)
• Desonate Use in Pregnancy & Breastfeeding
• Desonate Drug Interactions
• Desonate Support Group
• 0 Reviews for Desonate - Add your own review/rating

• Desonate Prescribing Information (FDA)


• Desonate Gel MedFacts Consumer Leaflet (Wolters Kluwer)


• Desonate Advanced Consumer (Micromedex) - Includes Dosage Information


• Desonate Consumer Overview


• DesOwen Cream MedFacts Consumer Leaflet (Wolters Kluwer)


• DesOwen Cream Kit Cream MedFacts Consumer Leaflet (Wolters Kluwer)


• Desowen Prescribing Information (FDA)


• LoKara Prescribing Information (FDA)


• LoKara Lotion MedFacts Consumer Leaflet (Wolters Kluwer)


• Verdeso Prescribing Information (FDA)


• Verdeso Consumer Overview


• Verdeso Foam MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Desonate with other medications

• Atopic Dermatitis
• Dermatitis
• Eczema
• Psoriasis

Where can I get more information?

• Your pharmacist can provide more information about desonide topical.

See also: Desonate side effects (in more detail)